A Phase 4 interventional study of rituximab [MabThera/Rituxan] and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 10 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-04.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 96th largest by enrollment, is one of 9 that started in 2007, is one of 38 in phase 4, and was the 24th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 112th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 28 in phase 4, and was the 39th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the safety and efficacy of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response or intolerance to one or more anti-TNF agents. Patients will receive MabThera 1000mg i.v. on days 1 and 15, and methotrexate (10-25mg/week p.o. or parenteral), together with methylprednisolone 100mg i.v. prior to infusion of MabThera. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: Methotrexate
Drug page: Rituximab
1000mg iv on days 1 and 15
10-25mg/week po or parenteral
Change From Baseline in Disease Activity Score Based on 28-Joint Count (DAS28)
DAS28 was calculated from the number of swollen joints, or swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (measured in millimeters per hour \[mm/hr\]), and Patient Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A clinically significant improvement in DAS28 was a change of at least 1.2 units.
Time frame: Week 24
Percentage of Participants Achieving American College of Rheumatology (ACR) Response
ACR20/50/70 response defined as greater than or equal to (≥)20 percent (%), 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%/50%/70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain, Patient Global Assessment of Disease Activity, Physician Global Assessment of Disease Activity, self-assessed disability based on the Health Assessment Questionnaire-Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
Time frame: Week 24
Percentage of Participants Achieving a Response by European League Against Rheumatism (EULAR) Category
Percentage of participants with a EULAR response at Week 24 based on a scale of good response, moderate response, or no response. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders have a change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders have a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders have a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.
Time frame: Week 24
Change From Baseline in HAQ-DI Score
The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set are scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person is required. The HAQ-DI score is calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".
Time frame: Week 24
| Milestone | Rituximab + Methotrexate (MTX) |
|---|---|
| Started | 36 |
| Completed | 35 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
DAS28 was calculated from the number of swollen joints, or swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (measured in millimeters per hour \[mm/hr\]), and Patient Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A clinically significant improvement in DAS28 was a change of at least 1.2 units.
| scores on a scale | Rituximab + MTX |
|---|---|
| Baseline | 5.51 ± 1.05 |
| Week 24 | 4.39 ± 1.21 |
| Change from Baseline to Week 24 | -1.12 ± 1.19 |
ACR20/50/70 response defined as greater than or equal to (≥)20 percent (%), 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%/50%/70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain, Patient Global Assessment of Disease Activity, Physician Global Assessment of Disease Activity, self-assessed disability based on the Health Assessment Questionnaire-Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
| percentage of participants | Rituximab + MTX |
|---|---|
| ACR20 | 2.78 |
| ACR50 | 0 |
| ACR70 | 0 |
Percentage of participants with a EULAR response at Week 24 based on a scale of good response, moderate response, or no response. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders have a change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders have a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders have a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.
| percentage of participants | Rituximab + MTX |
|---|---|
| Good response | 0 |
| Moderate response | 58.33 |
| No response | 41.67 |
The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set are scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person is required. The HAQ-DI score is calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".
| scores on a scale | Rituximab + MTX |
|---|---|
| Baseline | 1.07 ± 0.69 |
| Week 24 | 0.81 ± 0.65 |
| Change from Baseline to Week 24 | -0.26 ± 0.52 |
Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + MTX | — | 3/36 (8.3%) | 22/36 (61.1%) |
| Event | Rituximab + MTX |
|---|---|
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 1/36 |
| CholelithiasisHepatobiliary disorders | 1/36 |
| Back painMusculoskeletal and connective tissue disorders | 1/36 |
| Event | Rituximab + MTX |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/36 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/36 |
| DizzinessCardiac disorders | 2/36 |
| FatigueGeneral disorders | 2/36 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 2/36 |
| RashSkin and subcutaneous tissue disorders | 2/36 |
| HypertensionVascular disorders | 2/36 |
| LeukocytosisBlood and lymphatic system disorders | 1/36 |
| Mononucleosis syndromeBlood and lymphatic system disorders | 1/36 |
| Abdominal pain upperGastrointestinal disorders | 1/36 |
Intent-to-Treat (ITT) Population: all participants who recieved any part of an infusion.
| Age, Continuous(years) | Rituximab + MTX |
|---|---|
| Mean | 50.72 ± 13.42 |
| Sex: Female, Male(Participants) | Rituximab + MTX |
|---|---|
| Female | 33 |
| Male | 3 |
The record gives a start of Jul 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate